Managing CRVO and its complications

Article

In a recent satellite symposium, sponsored by Bayer, the topic of macular oedema following CRVO was discussed by a panel of experts. Here, we present a summary of this meeting, highlighting the key outcomes.

During this meeting a panel of experts discussed the clinical perspectives and insights into CRVO with a particular emphasis on the serious and vision-threatening complication of macular oedema. In this article, we will present a summary of the key outcomes from this meeting.

Overview of the disease

"CRVO accounts for 20% of all RVOs," Prof. Silva continued. Most patients will experience CRVO in only one eye, however, it can affect both in around 10% of cases.2

A further important aspect of CRVO is development of non-perfusion (ischaemia), which has been reported to occur in approximately 20% of CRVO cases.3 However, Prof. Silva noted that this differentiation is not necessarily an easy one to make but it is vital as the prognosis of the patient, even with treatment, is very different. "No-one who has the ischaemic form of CRVO will experience a complete recovery of vision over time," he stressed. "Fortunately, this form does not account for the majority of CRVO cases."

Macular oedema and CRVO

A common complication of CRVO and the main cause of visual acuity loss in these patients is macular oedema. "The pathophysiology is not completely understood," Prof. Silva said, "but we do know that we have blood clots in the central retinal vein at the level of the lamina cribosa."

Visual acuity loss is really the linchpin of the disease, noted Prof. Silva. "With low visual acuity, a lot of patients experience a detrimental effect on their quality of life and as such are even willing to undergo invasive treatment," he said. However, this is a chronic recurring disease and so treatment options that can abate the inflammatory effect of the oedema while also increasing visual acuity and not impeeding a patient's lifestyle are preferred.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.